Related Party Transactions - Additional Information (Details)					3 Months Ended		6 Months Ended
	Dec. 17, 2019 USD ($) shares	Dec. 16, 2019 USD ($) shares	Dec. 07, 2019 USD ($) shares	Oct. 02, 2018 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($) shares	Dec. 31, 2018 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)
Related Party Transaction [Line Items]
Other General and Administrative Expense					$ 2,000
Percentage of Direct Costs					30.00%
Percentage Of Net Sales Allocated For Royalty Payments					15.00%
Research and Development Expense					$ 1,012,085	$ 1,657,838	$ 2,494,490	$ 3,024,779
Accrued Royalties									$ 0	$ 0
Amortization expense on loan origination fee							(1,638)	0
Loss on exchange of shares					142,669		142,669
TheraCour
Related Party Transaction [Line Items]
Research and Development Expense				$ 25,000	543,108	$ 899,184	$ 1,119,315	$ 1,745,872
Series A Preferred stock
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares		10,000					110,774
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 39,301					$ 438,242
Converted value to common shares		0.285
Amortization expense on loan origination fee					$ 1,638		$ 1,638
Series A Preferred stock | TheraCour
Related Party Transaction [Line Items]
Series A shares issued in exchange of deferred development fees owed (in shares) | shares		10,000	100,000
Deferred development fees exchanged for shares			$ 250,000
Series A Preferred stock | TheraCour
Related Party Transaction [Line Items]
Series A shares issued in exchange of deferred development fees owed (in shares) | shares	100,000
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 392,669
Deferred development fees exchanged for shares	250,000
Loss on exchange of shares	$ 142,669